Thursday, September 25, 2014 10:50:00 PM
Here is the perfect example of where we will be heading with Sanofi. This deal occurred in January 2014.
Sanofi to Buy 12% of Alnylam, Expands Rare-Disease Drug Deal
The $700 million deal strengthens the development partnership of the two, while reinforcing Sanofi's commitment to rare disease
French drugmaker Sanofi will buy a 12 percent stake in Alnylam Pharmaceuticals Inc for $700 million and deepen their partnership to develop drugs for rare genetic diseases.
The companies said in a joint statement on Monday that Sanofi would buy Alnylam shares for about $80 each, representing a 27 percent premium compared to their average price over the past 30 days.
The partnership between Sanofi and Alnylam began in 2012, the year after Sanofi jumped into the business of treating rare genetic diseases by paying more than $20 billion for U.S. biotechnology company Genzyme, a leader in the field.
Share price January 3rd 2012. $8.33 per share
September 2012 partnership announced with Sanofi. $20.74
January 10, 2014 share price close of market $66.21 per share.
Announcement of a purchase of 12% interest in Alnylam by Sanofi prior to market open on January 13, 2014 market share price at open $85.36 per share and at market close 1/13/2014 $93.28 per share.
So today's MannKind share price at $6.10 per share could be just like Alnylam's. It took about 16 months after partnership for Sanofi to buy 12% of Alnylam. That now stands today at 13%.
WI'll Sanofi do the same with MannKind? A blockbuster type drug they can sell for many years in the USA and later in a 120 countries. I think we will have a winner if we just sit back for 12 to 18 months. I don't think it will take Sanofi 18 months to buy a 10% or more interest in MannKind. I predict this will happen before the end of 2014 now that the HSR approval is behind us.
Recent MNKD News
- MannKind Announces Clearance from PMDA to Initiate Phase 3 Clinical Trial (ICoN-1) in Japan Evaluating Clofazimine Inhalation Suspension for the Treatment of Nontuberculous Mycobacterial (NTM) Lung Disease • GlobeNewswire Inc. • 09/18/2024 10:15:00 AM
- MannKind to Present at 2024 Cantor Fitzgerald Global Healthcare Conference • GlobeNewswire Inc. • 09/10/2024 08:30:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 09/05/2024 01:11:49 AM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 09/03/2024 08:25:31 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 08/30/2024 08:35:07 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 08/30/2024 01:00:08 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 08/30/2024 01:00:06 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 08/30/2024 01:00:05 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 08/30/2024 01:00:03 AM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 08/29/2024 09:23:28 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 08/29/2024 08:15:52 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 08/29/2024 08:15:28 PM
- MannKind to Present at Upcoming Conferences • GlobeNewswire Inc. • 08/27/2024 08:30:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/14/2024 12:03:59 PM
- Kent Kresa to Retire from MannKind’s Board of Directors; Steven B. Binder to be Appointed to the Board • GlobeNewswire Inc. • 08/14/2024 12:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/07/2024 12:05:43 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/07/2024 12:05:34 PM
- MannKind Corporation Reports 2024 Second Quarter Financial Results: Provides Clinical Development Update • GlobeNewswire Inc. • 08/07/2024 12:00:00 PM
- US Index Futures Rise Amid Earnings Season Optimism, Oil Prices Rebound • IH Market News • 08/07/2024 09:49:12 AM
- MannKind Launches Educational Website to Raise Awareness of NTM Lung Disease • GlobeNewswire Inc. • 07/31/2024 10:30:00 AM
- MannKind Corporation to Hold 2024 Second Quarter Financial Results Conference Call on August 7, 2024 • GlobeNewswire Inc. • 07/30/2024 08:30:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 07/17/2024 11:50:35 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 07/17/2024 11:50:18 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 07/17/2024 11:50:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 07/17/2024 11:49:45 PM
VHAI - Vocodia Partners with Leading Political Super PACs to Revolutionize Fundraising Efforts • VHAI • Sep 19, 2024 11:48 AM
Dear Cashmere Group Holding Co. AKA Swifty Global Signs Binding Letter of Intent to be Acquired by Signing Day Sports • DRCR • Sep 19, 2024 10:26 AM
HealthLynked Launches Virtual Urgent Care Through Partnership with Lyric Health. • HLYK • Sep 19, 2024 8:00 AM
Element79 Gold Corp. Appoints Kevin Arias as Advisor to the Board of Directors, Strengthening Strategic Leadership • ELMGF • Sep 18, 2024 10:29 AM
Mawson Finland Limited Further Expands the Known Mineralized Zones at Rajapalot: Palokas step-out drills 7 metres @ 9.1 g/t gold & 706 ppm cobalt • MFL • Sep 17, 2024 9:02 AM
PickleJar Announces Integration With OptCulture to Deliver Holistic Fan Experiences at Venue Point of Sale • PKLE • Sep 17, 2024 8:00 AM